tanshinone has been researched along with Oligohydramnios in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Dai, D; Hua, Y; Lan, Y; Pan, S; Peng, L; Shao, H | 1 |
| Chen, B; Hua, Y; Lan, Y; Pan, S; Ying, X; Zhou, Y | 1 |
2 other study(ies) available for tanshinone and Oligohydramnios
| Article | Year |
|---|---|
Tanshinone IIA increased amniotic fluid volume through down-regulating placental AQPs expression via inhibiting the activity of GSK-3β.
Topics: Abietanes; Amniotic Fluid; Animals; Aquaporins; Cell Line, Tumor; Endothelial Cells; Female; Glycogen Synthase Kinase 3 beta; Humans; Mice; Oligohydramnios; Placenta; Pregnancy | 2022 |
Tanshinone IIA changed the amniotic fluid volume and regulated expression of AQP1 and AQP3 in amniotic epithelium cells: a promising drug treating abnormal amniotic fluid volume.
Topics: Amnion; Amniotic Fluid; Animals; Aquaporin 1; Aquaporin 3; Epithelium; Female; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Knockout; Oligohydramnios; Pregnancy | 2023 |